A year in diabetic nephropathy


  • Jovanna Tsoutsouki The Royal London Hospital
  • Tahseen Ahmad Chowdhury The Royal London Hospital




diabetes mellitus, type 2, nephropathy, post-transplant diabetes


Whilst 2020 was a year of unique healthcare challenges, in people with type 2 diabetes and diabetic kidney disease (DKD), it was a year of seminal progress. Randomised clinical trials have shown a significant benefit of sodium-glucose transporter-2 inhibitors in patients with DKD, and guidelines now suggest these drugs should be considered in all patients with type 2 diabetes and DKD irrespective of glucose control. Glucagon-like peptide-1 receptor agonists have shown some benefit in reducing progression of albuminuria in DKD, and should also be considered early in the therapeutic pathway. There are new guidelines on the management of post-transplant diabetes, and some new ideas in the management of diabetes in patients on haemodialysis. This article aims to review the year in diabetic nephropathy.

Author Biographies

Jovanna Tsoutsouki, The Royal London Hospital

Specialist Registrar in Endocrinology and Diabetes

Department of Diabetes

The Royal London Hospital

Tahseen Ahmad Chowdhury, The Royal London Hospital

Consultant in Diabetes

Department of Diabetes

The Royal London Hospital



Kainz A, Hronsky M, Stel VS, et al. Prediction of prevalence of chronic kidney disease in diabetic patients in countries of the European Union up to 2025. Nephrol Dial Transplant 2015;30(Suppl 4):iv113–8. https://doi.org/10.1093/ndt/gfv073

Adler AI, Stevens RJ, Manley SE, et al. on behalf of the UKPDS GROUP Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003;63:225–32. https://doi.org/10.1046/j.1523-1755.2003.00712.x

Koye DN, Shaw JE, Reid CM, et al. Incidence of chronic kidney disease among people with diabetes: a systematic review of observational studies. Diabet Med 2017;34:887–901. https://doi.org/10.1111/dme.13324

Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012;380:1662–73. https://doi.org/10.1016/S0140-6736(12)61350-6

Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359–64. https://doi.org/10.1016/S0140-6736(98)10363-X

Fried L, Emanuele N, Zhang J, et al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 2013;369:1892–903. https://doi.org/10.1056/NEJMoa1303154

Parving H, Brenner B, McMurray J, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204–13. https://doi.org/10.1056/NEJMoa1208799

De Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013;369: 2492–503. https://doi.org/10.1056/NEJMoa1306033

Mann J, Green D, Jamerson K, et al. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010;21(3):527–35. https://doi.org/10.1681/ASN.2009060593

Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care 2016;39(Suppl 2):S165–71. https://doi.org/10.2337/dcS15-3006

Van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 2020;97:202–12. https://doi.org/10.1016/j.kint.2019.09.013

Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 2016;375:323–34. https://doi.org/10.1056/NEJMoa1515920

Barnett AH, Mithal A, Manassie J, et al. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2014;2:369–84. https://doi.org/10.1016/S2213-8587(13)70208-0

Packer M, Anker J, Butler G, et al, for the Emperor-Reduced Trial Investigators. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–24. https://doi.org/10.1056/NEJMoa2022190

Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57. https://doi.org/10.1056/NEJMoa1611925

Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019;380:2295–306. https://doi.org/10.1056/NEJMoa1811744

McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med 2020;383:1436–46. https://doi.org/10.1056/NEJMoa2024816

Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019;380:347–57. https://doi.org/10.1056/NEJMoa1812389

Lo KB, Gul F, Ram P, et al. The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: a systematic review and meta-analysis. Cardiorenal Med 2020;10:1–10. https://doi.org/10.1159/000503919

Cherney DZ, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPAREG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 2017;5:610–21. https://doi.org/10.1016/S2213-8587(17)30182-1

Neuen BL, Ohkuma T, Neal B, et al. Effect of canagliflozin on renal and cardiovascular outcomes across different levels of albuminuria: data from the CANVAS Program. J Am Soc Nephrol 2019;30:2229–42. https://doi.org/10.1681/ASN.2019010064

Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol 2020;8:27–35. https://doi.org/10.1016/S2213-8587(19)30384-5

Pasternak B, Wintzell V, Melbye M, et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study. BMJ 2020;369:m1186. https://doi.org/10.1136/bmj.m1186

Empagliflozin SPC. www.medicines.org.uk/emc/product/5441 [Accessed January 2021].

Dapagliflozin SPC. www.medicines.org.uk/EMC/medicine/27188 [Accessed January 2021].

Canagliflozin SPC. www.medicines.org.uk/emc/medicine/28400 [Accessed January 2021].

Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487–93. https://doi.org/10.2337/dci19-0066

Thong KY, Yadagiri M, Barnes DJ, et al. Clinical risk factors predicting genital fungal infections with sodium-glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. Prim Care Diabetes 2018;12:45–50. https://doi.org/10.1016/j.pcd.2017.06.004

FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. US Food and Drug Administration. www.fda.gov/Drugs/DrugSafety/ucm475463.htm

Qian BB, Chen Q, Li L, Yan C-F. Association between combined treatment with SGLT2 inhibitors and metformin for type 2 diabetes mellitus on fracture risk: a meta-analysis of randomized controlled trials. Osteoporosis Int 2020;31:2313–20. https://doi.org/10.1007/s00198-020-05590-y

Cahn A, Melzer-Cohen C, Pollack R, Chodick G, Shalev V. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes Obes Metab 2019;21:340–8. https://doi.org/10.1111/dom.13532

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015; 373:2247–57. https://doi.org/10.1056/NEJMoa1509225

Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017; 377:1228–39. https://doi.org/10.1056/NEJMoa1612917

Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 2017;377:839–48. https://doi.org/10.1056/NEJMoa1616011

Davies MJ, Bain SC, Atkin SL, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 2015;39:222–30. https://doi.org/10.2337/dc14-288

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121–30. https://doi.org/10.1016/S0140-6736(19)31149-3

Gerstein HC, Colhoun H, Dagenais G, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 2019;394:131–8. https://doi.org/10.1016/S0140-6736(19)31150-X

Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. https://doi.org/10.1056/NEJMoa1607141

Mosenzon O, Blicher TM, Rosenlund S, et al, PIONEER 5 Investigators. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019;7:515–27. https://doi.org/10.1016/S2213-8587(19)30192-5

Idorn T, Knop FK, Jørgensen MB, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: an investigator-initiated, placebo-controlled, double-blind, parallel-group, randomized trial. Diabetes Care 2016;39:206–13. https://doi.org/10.2337/dc15-1025

Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol 2018;6(8):605-17.

Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841–51. https://doi.org/10.1056/NEJMoa1901118

Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019;7:776–85. https://doi.org/10.1016/S2213-8587(19)30249-9

Nauck MA, Meier JJ, Cavender MA, El Aziz MA, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017;136:849–70. https://doi.org/10.1161/CIRCULATIONAHA.117.028136

Mann JFE, Hansen T, Idorn T, et al. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials. Lancet Diabetes Endocrinol 2020;8:880–93. https://doi.org/10.1016/S2213-8587(20)30313-2

https://clinicaltrials.gov/ct2/show/NCT03819153 [Accessed January 2021]

Bakris GL, Agarwal R, Anker SD, et al; FIDELIO-DKD Investigators. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020;383(23):2219–29. https://doi.org/10.1056/NEJMoa2025845

Yates CJ, Fourlanos S, Hejlmesaeth J, Colman PG, Cohney SG. New onset diabetes after kidney transplantation – changes and challenges. Am J Transplant 2012;12:820–8. https://doi.org/10.1111/j.1600-6143.2011.03855.x

Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010;56:1127–39. https://doi.org/10.1053/j.ajkd.2010.06.027

Chowdhury TA, Wahba M, Mallik R, et al. Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation. Diabet Med 2021; Jan 12:e14523. https://doi.org/10.1111/dme.14523

Rodrigo E, Santos L, Piñera C, et al. Prediction at first year of incident new-onset diabetes after kidney transplantation by risk prediction models. Diabetes Care 2012;35:471–3. https://doi.org/10.2337/dc11-2071

Øzbay LA, Smidt K, Mortensen DM, et al. Cyclosporin and tacrolimus impair insulin secretion and transcriptional regulation in INS-1E beta-cells. Br J Pharmacol 2011;162(1):136–46. https://doi.org/10.1111/j.1476-5381.2010.01018.x

Webster AC, Woodroffe RC, Tayloer RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. BMJ 2005;331:810. https://doi.org/10.1136/bmj.38569.471007.AE

Gupta S, Pollack T, Fulkerson C, et al. Hyperglycemia in the posttransplant period: NODAT vs posttransplant diabetes mellitus. J Endocr Soc 2018;2(11):1314–19. https://doi.org/10.1210/js.2018-00227

Sharif A, Hecking M, de Vries APR, et al. Proceedings from an international consensus meeting on posttransplant diabetes mellitus: recommendations and future directions. Am J Transplant 2014;14:1992–2000. https://doi.org/10.1111/ajt.12850

Kasiske B, Zeier MG, Chapman JR, et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010;77(4):299–311. https://doi.org/10.1038/ki.2009.377

Singh P, Pesavento TE, Washburn K, Walsh D, Meng S. Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients. Diabetes Obes Metab 2019; 21(4):1061–5. https://doi.org/10.1111/dom.13619

Halden TAS, Kvitne KE, Midtvedt K, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus. Diabetes Care 2019;42(6):1067–74. https://doi.org/10.2337/dc19-0093

Oberholzer J, Thielke J, Hatipoglu B, Testa G, Sankary HN, Benedetti E. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplant Proc 2005;37:999–1000. https://doi.org/10.1016/j.transproceed.2004.12.085

Jørgensen MB, Idorn T, Knop FK, et al. Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients. Nephrol Dial Transplant 2015;30(3):513–20. https://doi.org/10.1093/ndt/gfu327

Mak RHK, DeFronzo RA. Glucose and insulin metabolism in uremia. Nephron 1992;61(4):377–82. https://doi.org/10.1159/000186953

Kazempour-Ardebili S, Lecamwasam VL, Dassanyake T, et al. Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes. Diabetes Care 2009;32(7):1137–42. https://doi.org/10.2337/dc08-1688

Frankel A, Kazempour-Ardebili S, Bedi R, Chowdhury TA, et al. Management of adults with diabetes on the haemodialysis unit: summary of new guidance from the Joint British Diabetes Societies and Renal Association. Diabet Med 2018;35:1018–26. https://doi.org/10.1111/dme.1367

Mirani M, Berra C, Finazzi S, et al. Inter-day glycemic variability assessed by continuous glucose monitoring in insulin-treated type 2 diabetes patients on hemodialysis. Diabetes Technol Ther 2010;12(10):749–53. https://doi.org/10.1089/dia.2010.0052

NHS England. Flash Glucose Monitoring: National arrangements for funding relevant diabetes patients. https://www.england.nhs.uk/wp-content/uploads/2019/03/National-arrangements-for-funding-of-relevant-diabetes-patients-June-2020-Updated-final.pdf [Accessed February 2021]

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The task force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035–87. https://doi.org/10.1093/eurheartj/eht108

Bhatt DL, Szarek M, Pitt B, et al, for the SCORED Trial Investigators. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 2021;384(2):129–39. https://doi.org/10.1056/NEJMoa2030186

Cannon CP, Pratley R, Dagogo-Jack S, et al, VERTIS CV Investigators. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 2020;383(15):1425–35. https://doi.org/10.1056/NEJMoa2004967






Current Topics